This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alsmadi, O.
Right arrow Articles by Tilley, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alsmadi, O.
Right arrow Articles by Tilley, S. A.

 Previous Article  |  Next Article 

J. Virol., 01 1998, 286-293, Vol 72, No. 1
Copyright © 1998, American Society for Microbiology

Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities

O Alsmadi and SA Tilley
Public Health Research Institute, New York, New York 10016, USA.

The characteristics of antibody-dependent cellular cytotoxicity (ADCC) directed by a panel of human and chimpanzee antienvelope (anti-Env) monoclonal antibodies (MAbs) of different epitope specificities were studied; this was accomplished by using target cells expressing human immunodeficiency virus type 1 (HIV-1) Envs of either primary or laboratory-adapted strains. Human MAbs of similar apparent affinities (1 x 10(9) to 2 x 10(9) liters/mol) against either a "cluster II"- overlapping epitope of gp41 or against the CD4 binding site, V3 loop, or C5 domain of gp120 directed substantial and comparable levels of specific lysis against targets infected with laboratory-adapted strains of HIV-1. As expected, those MAbs specific for relatively conserved regions of Env generally exhibited ADCC activity against a broader range of HIV-1 strains than those directed against variable epitopes. Significant ADCC activities of selected MAbs against primary isolate Env-expressing cells were demonstrated. In addition, a new ADCC epitope in the V2 domain of gp120 was defined. CD56+ cells were demonstrated to be the effector cells in these studies by fluorescence-activated cell sorting followed by ADCC assays. Notably, all anti-Env MAbs tested in this study, including MAbs directed against each of the known neutralization epitope clusters in gp120, directed significant levels of ADCC against targets expressing Env of one or more HIV-1 strains. These results imply that many, if not most, HIV-1-neutralizing human Abs of high affinity (> or = 3 x 10(8) liters/mol in these studies) and of the immunoglobulin G1 (IgG1) subclass (i.e., the predominate IgG subclass) are capable of directing ADCC. Since neutralizing Abs have been associated with long-term survival following HIV-1 infection, this suggests that ADCC activity may be beneficial in vivo.


This article has been cited by other articles:

  • Forthal, D. N., Gilbert, P. B., Landucci, G., Phan, T. (2007). Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate. J. Immunol. 178: 6596-6603 [Abstract] [Full Text]  
  • Forthal, D. N., Landucci, G., Cole, K. S., Marthas, M., Becerra, J. C., Van Rompay, K. (2006). Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.. J. Virol. 80: 9217-9225 [Abstract] [Full Text]  
  • Yamada, T., Watanabe, N., Nakamura, T., Iwamoto, A. (2004). Antibody-Dependent Cellular Cytotoxicity via Humoral Immune Epitope of Nef Protein Expressed on Cell Surface. J. Immunol. 172: 2401-2406 [Abstract] [Full Text]  
  • Subbramanian, R. A., Xu, J., Toma, E., Morisset, R., Cohen, E. A., Menezes,, J., Ahmad, A. (2002). Comparison of Human Immunodeficiency Virus (HIV)-Specific Infection-Enhancing and -Inhibiting Antibodies in AIDS Patients. J. Clin. Microbiol. 40: 2141-2146 [Abstract] [Full Text]  
  • Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., Parren, P. W. H. I. (2001). Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1. J. Virol. 75: 12161-12168 [Abstract] [Full Text]